Using NMN to Improve Embryo Development in IVF Patients
Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity and IVF Success Rate in Patients Who Have Experienced IVF Failures.
This study is testing if taking a supplement called NMN can help improve embryo development and success rates for women aged 32-42 who have had repeated IVF failures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 32 Years to 42 Years |
| Sex | Female |
| Sponsor | Sunkaky Medical Cooperation Industry-sponsored |
| Locations | 1 site (Osaka, Osaka) |
| Trial ID | NCT06629636 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Nicotinamide Mononucleotide (NMN) supplementation in enhancing embryo development and increasing success rates in patients who have experienced repeated failures in in vitro fertilization (IVF). The research focuses on the relationship between mitochondrial function and oocyte quality, particularly in women aged 32-42 with a history of low embryo quality. Participants will receive either NMN capsules or a placebo, and the outcomes will be measured based on embryo development capacity and overall IVF success. The study aims to address the challenges posed by reproductive aging and improve fertility outcomes for affected women.
Who should consider this trial
Good fit: Ideal candidates are women aged 32-42 who have experienced at least one previous embryo implantation failure and have a history of low embryo quality.
Not a fit: Patients with severe sperm abnormalities or significant uterine or ovarian issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve IVF success rates for women facing repeated failures due to age-related declines in oocyte quality.
How similar studies have performed: While studies on NMN supplementation in animal models have shown promise, this specific application in human IVF settings is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Agree to participate in the study * 32-42 years old * Having at least one previous embryo implantation failure * History of low Embryo quality at day3 or day5 (according to Veeck's and Gardner's Criteria) * No major uterine or ovarian abnormalities * BMI level 18-25kg/m2 Exclusion Criteria: * Ovarian endometriosis with Chocolate cysts (AFS type 3 and 4) * Patients who have taken different supplements such as coenzyme Q10, vitamin E, carnitine,niacin, nicotinamide, or other vitamin B3-related etc. within the previous month * Any medical contraindication of oocyte retrieval or subsequent procedures * Couples where the husband presents with severe sperm abnormalities * Couples where the husband presents \<5 million/mL motile sperm * Uterine structural anomalies * Polycystic ovaries * Premature ovarian failure * Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc. * Individuals who need drug treatment for any mental illness such as epilepsy and depression. * Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc. * Cancer patients or receiving chemo/radiotherapy treatment within the past 3 years.
Where this trial is running
Osaka, Osaka
- IVF Namba Clinic, Sankaky Medical Corporation — Osaka, Osaka, Japan (Recruiting)
Study contacts
- Principal investigator: Yoshiharu M., Yoshiharu Morimoto, MD, PhD — Sankaky Medical Corporation
- Study coordinator: Udayanga KGS., Udayanga Gamage, BVSc, PhD
- Email: udayanga646@ivfjapan.com
- Phone: +81 90 9823 8477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.